PTC Therapeutics (PTCT) – Research Analysts’ Weekly Ratings Updates

PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates:

• 8/22/2026 – PTC Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/17/2026 – PTC Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 8/14/2026 – PTC Therapeutics had its price target raised by Barclays PLC from $120.00 to $122.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – PTC Therapeutics had its price target raised by Wells Fargo & Company from $106.00 to $109.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – PTC Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/1/2026 – PTC Therapeutics was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 7/31/2026 – PTC Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/31/2026 – PTC Therapeutics had its price target raised by Morgan Stanley from $93.00 to $104.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – PTC Therapeutics had its price target raised by Wells Fargo & Company from $93.00 to $106.00. They now have an “overweight” rating on the stock.
• 7/20/2026 – PTC Therapeutics had its price target lowered by Wells Fargo & Company from $95.00 to $93.00. They now have an “overweight” rating on the stock.
• 7/16/2026 – PTC Therapeutics had its price target raised by Cantor Fitzgerald from $124.00 to $130.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – PTC Therapeutics had its price target raised by Royal Bank Of Canada from $82.00 to $85.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – PTC Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.

Insiders Place Their Bets

In other news, Director Mary L. Smith sold 15,834 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $90.00, for a total value of $1,425,060.00. Following the sale, the director directly owned 21,813 shares of the company’s stock, valued at $1,963,170. This represents a 42.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Schmertzler sold 12,500 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $73.32, for a total transaction of $916,500.00. Following the completion of the transaction, the director owned 1,374,094 shares of the company’s stock, valued at approximately $100,748,572.08. The trade was a 0.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 205,343 shares of company stock valued at $16,774,704 in the last 90 days. Corporate insiders own 5.30% of the company’s stock.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.